In vitro analysis of rifampicin and its effect on quality control tests of rifampicin containing dosage forms.
The chemical stability of rifampicin both in solid state and various media has widely been investigated. While rifampicin is appreciably stable in solid-state, its decomposition rate is very high in acidic as well as in alkaline medium and a variety of decomposition products were identified. The literature reports on highly variable rifampicin decomposition in acidic medium. Hence, the objective of this investigation was to study possible reasons responsible for this variability. For this purpose, filter validation and correlation between rifampicin and its degradation products were developed to account for the loss of rifampicin in acidic media. For analysis of rifampicin with or without the presence of isoniazid, a simple and accurate method was developed using high performance chromatography recommended in FDC monographs of the United States Pharmacopoeia. Using the equations developed in this investigation, the amount of rifampicin degraded in the acidic media was calculated from the area under curve of the degradation products. Further, it was proved that in a dissolution study, the colorimetric method of analysis recommended in the United States Pharmacopoeia provides accurate results regarding rifampicin release. Filter type, time of injection as well as interpretation of data are important factors that affect analysis results of rifampicin in in vitro studies and quality control.
Agrawal
S
S
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Nagar, Punjab, India.
Panchagnula
R
R
D000904:Antibiotics, Antitubercular / Q000032:analysis*; D000995:Antitubercular Agents / Q000032:analysis; D019540:Area Under Curve; D002851:Chromatography, High Pressure Liquid; D004304:Dosage Forms; D004338:Drug Combinations; D005374:Filtration; D007538:Isoniazid / Q000032:analysis; D011786:Quality Control; D012293:Rifampin / Q000032:analysis*; D012995:Solubility; D013607:Tablets
D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D004304:Dosage Forms; D004338:Drug Combinations; D013607:Tablets; D007538:Isoniazid; D012293:Rifampin